The International URBAN Alcohol Research Collaboration on HIV/AIDS (ARCH) Center
Project Number3P01AA029541-02S1
Former Number5P01AA029541-02
Contact PI/Project LeaderSAMET, JEFFREY H.
Awardee OrganizationBOSTON MEDICAL CENTER
Description
Abstract Text
PROJECT SUMMARY / ABSTRACT
Tuberculosis (TB) is the leading cause of death from a single infectious agent and the leading cause of death
in people with HIV (PWH). An estimated 8.5 million people with TB are cured every year but many do not
return to full health. Up to half of those completing treatment for pulmonary TB have post-TB lung disease, a
disabling under-diagnosed group of lung deficits. Lung deficits at TB treatment completion are the strongest
predictors of post-TB lung disease severity up to a year later. Alcohol and HIV are associated with lung
immune dysfunction and alcohol use is associated with delayed TB diagnosis, increasing the risk of lung injury
during active TB disease. However, it is not known whether alcohol use is associated with post-TB lung
disease in PWH. We hypothesize that hazardous drinking increases susceptibility to and worsens post-TB lung
disease in PWH. Our objective is to investigate hazardous drinking (Alcohol Use Disorders Identification Test
[AUDIT] ≥8) as a modifiable risk factor for post-TB lung disease in PWH. To achieve this, we propose an 18-
month observational study of 200 PWH completing pulmonary TB treatment in Mbarara, Uganda. We will
evaluate the following post-TB lung disease outcomes: functional exercise capacity (primary outcome
assessed by 6-minute walk distance), lung physiology (pulmonary function tests), anatomy (CT scan), and lung
infections. The primary exposure is past-year hazardous drinking. Secondary alcohol measures will include 30-
day Timeline Followback (calendar-based method of alcohol use recall) and phosphatidylethanol (PEth; a
biomarker of recent alcohol use). Our expertise spans alcohol use, HIV, TB, pulmonology, epidemiology, and
biostatistics. Our primary aim (Aim 1a) is to determine the relationship between past-year hazardous drinking
and post-TB lung disease. In Aim 1b we assess the association of past-month heavy drinking and post-TB
lung disease progression over time. In Aim 1c we explore whether smoking modifies the association of past-
month heavy drinking and post-TB lung disease progression over time. Heavy drinking in Aims 1b and 1c is
defined by Timeline Followback as ≥7 drinks/week (women) or ≥14 drinks/week (men) or PEth>200 ng/mL. In
Aim 2, we will qualitatively evaluate factors that can improve tailoring of pharmaco-behavioral alcohol and
smoking interventions in PWH receiving TB treatment. We will conduct in-depth interviews with 24 PWH during
or after inpatient TB treatment and 12 TB healthcare providers. IMPACT: We will determine the association
of alcohol use and post-TB lung disease in PWH. Our quantitative and qualitative data will lay the
foundation for future work to tailor alcohol and smoking interventions to improve long-term health in HIV/TB co-
infection.
Public Health Relevance Statement
PROJECT NARRATIVE
Untreated tuberculosis (TB) is deadly, particularly for people with HIV (PWH); but 85% of the 10 million people
who fall ill with TB are cured. Despite TB treatment, up to half of TB patients have lung disease that persists
(post-TB lung disease). We are 1) studying whether hazardous alcohol consumption contributes to post-TB
lung disease in PWH and 2) exploring TB patient and clinician perspectives to design effective interventions to
reduce hazardous drinking and improve lung and overall health in PWH who are treated for TB.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AddressAlcohol abuseAlcohol consumptionAlcoholsAnatomyBehavioralBiological MarkersBiometryBronchiectasisCOVID-19CalendarCarbon MonoxideCause of DeathCollaborationsDataDiagnosisDiffusionDiseaseDisease OutcomeDisease ProgressionEffectiveness of InterventionsEpidemiologyEthanol toxicityFoundationsFutureGoalsHIVHIV/AIDSHIV/TBHealthHealth PersonnelHeavy DrinkingHigh PrevalenceImmune System DiseasesImmunologicsImmunologyInfectious AgentInpatientsInternationalInterventionInterviewKnowledgeLinkLungLung diseasesLung infectionsMalnutritionMeasuresMethodsObservational StudyOutcomeOutcome AssessmentPatientsPerceptionPersonsPhysiologicalPhysiologyPneumoniaPredispositionProductivityPulmonary Function Test/Forced Expiratory Volume 1Pulmonary TuberculosisPulmonary function testsPulmonologyReadinessResearchRespiratory Signs and SymptomsRiskRisk FactorsScanningSeverity of illnessSmokingTestingTimeToxic effectTranslatingTuberculosisTuberculosis diagnosisUgandaVital capacityWalkingWomanWorkX-Ray Computed Tomographyalcohol effectalcohol interventionalcohol researchalcohol use disorderbehavioral pharmacologyco-infectiondesigneffective interventionexercise capacityfallshazardous drinkingimprovedinterestlung injurymenmodifiable riskphosphatidylethanolprimary outcomesecondary outcomesmoking interventionsmoking prevalencesubstance usetimelinetreatment adherencetuberculosis treatment
National Institute on Alcohol Abuse and Alcoholism
CFDA Code
273
DUNS Number
005492160
UEI
JZ8RQC4EMDZ5
Project Start Date
01-September-2022
Project End Date
31-August-2026
Budget Start Date
01-September-2022
Budget End Date
31-August-2023
Project Funding Information for 2023
Total Funding
$109,899
Direct Costs
$109,899
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2023
National Institute on Alcohol Abuse and Alcoholism
$109,899
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3P01AA029541-02S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3P01AA029541-02S1
Patents
No Patents information available for 3P01AA029541-02S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3P01AA029541-02S1
Clinical Studies
No Clinical Studies information available for 3P01AA029541-02S1
News and More
Related News Releases
No news release information available for 3P01AA029541-02S1
History
No Historical information available for 3P01AA029541-02S1
Similar Projects
No Similar Projects information available for 3P01AA029541-02S1